Rock Creek Pharmaceuticals, Inc.

RCPIQ

US7720812046

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2020	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
2020	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Rock Creek Pharmaceuticals, Inc. Announces Resignation of Edward J. McDonnell as Directors

April 08, 2015 at 05:20 pm EDT

On April 2, 2015, the Board of Directors of Rock Creek Pharmaceuticals, Inc. received resignation message from Edward J. McDonnell notifying the company of Mr. McDonnell's resignation from his position on the Board of Directors over a disagreement regarding the company's drug development regulatory strategy.

Latest news about Rock Creek Pharmaceuticals, Inc.

Rock Creek Pharmaceuticals, Inc. Went Out of Business	20-12-07	CI
Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	20-02-05	CI
Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	18-12-20	CI
Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	18-01-10	CI
Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	16-09-27	CI
Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	16-08-29	CI
Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	16-08-10	CI
Rock Creek Pharmaceuticals, Inc. Announces Board Changes	16-07-08	CI
Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	16-06-08	CI
Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	16-03-29	CI
Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	16-03-22	CI
Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	16-03-21	CI
Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	15-11-19	CI
Rock Creek Pharmaceuticals, Inc.(OTCPK:RCPI) dropped from MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	15-11-06	CI
Rock Creek Pharmaceuticals, Inc.(OTCPK:RCPI) dropped from S&P TMI Index	15-11-06	CI
Rock Creek Pharmaceuticals, Inc.(OTCPK:RCPI) dropped from CRSP US Total Market Index	15-11-05	CI
Rock Creek Pharmaceuticals, Inc.(NasdaqCM:RCPI) dropped from NASDAQ Composite Index	15-11-04	CI
Rock Creek Pharmaceuticals, Inc. announced that it has received $20 million in funding from Hudson Bay Capital Management LP. and other investors.	15-10-14	CI
Rock Creek Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Hudson Bay Capital Management LP, and other investors.	15-10-13	CI
Certain Common Stock of Rock Creek Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-SEP-2015.	15-09-13	CI
Rock Creek Pharmaceuticals, Inc. Announces Executive Changes	15-08-20	CI
Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2015; Announces Targeting of Dermatological Disease, Updated Clinical and Regulatory Strategy	15-08-10	CI
Rock Creek Pharmaceuticals, Inc. Announces an Update on its Clinical and Regulatory Drug Development Activities	15-06-11	CI
Rock Creek Pharmaceuticals, Inc. Announces Executive Changes	15-06-10	CI
Rock Creek Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015	15-05-27	CI

Chart Rock Creek Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCK CREEK PHARMACEUTICALS, INC.	-.--%	17.04K
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.60%	364B
MERCK & CO., INC.	+20.83%	326B
ABBVIE INC.	+5.69%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.77%	167B
PFIZER, INC.	+0.10%	161B

Other Pharmaceuticals